Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Stockspawkon Jun 08, 2018 2:23pm

235 Views

Post# 28147214

Timelines

Some Upcoming Dates For ATE:

- June 21 Warrants Expire

- June 25 General Annual Meeting

- June 30 Secondary Endpoints Results Will Be Out (on or before this date)

- July XX P2 Large Trial Begins

- Dec. XX Warrants Expire

I am sure that there are more dates of events/catalysts that will take place, but any one of these things can move the SP in a north direction. I feel that 6-8 months from now we will be in a much better place. IMO

Bullboard Posts

Gold, growth and sustainability in focus for Mandalay Resources